International, Multi-center Post Authorization Surveillance Study on the Use of Nebido to Assess Tolerability and Treatment Outcomes in Daily Clinical Practice (IPASS Nebido).
Phase of Trial: Phase IV
Latest Information Update: 07 Dec 2012
At a glance
- Drugs Testosterone undecanoate (Primary)
- Indications Hypogonadism
- Focus Adverse reactions
- Acronyms IPASS Nebido
- Sponsors Bayer; Bayer HealthCare Pharmaceuticals
- 22 Mar 2011 Final results presented at the 26th Congress of the European Association of Urology.
- 23 Sep 2010 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
- 23 Sep 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.